Mouse Monoclonal MAGEA3 Antibody
| Catalog number: | B2022292 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL |
| Molecular Weight or Concentration: | 34.747 kDa |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Mouse MAGEA3 Monoclonal Antibody, Monoclonal Antibody against MAGEA3, MAGEA3 Mouse Antibody, Mouse Anti-MAGEA3 Antibody, MAGEA3 Mouse Monoclonal, MAGEA3 Antibody (Mouse), Mouse MAGEA3 Antibody, MAGEA3 Monoclonal, Anti-MAGEA3 Mouse Monoclonal Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kato, T., et al. (2018). MAGEA3 expression in human tumors and its potential as a target for immunotherapy. *Journal of Immunotherapy*, 41(5), 215-223.
- Kato, T., et al. (2019). The role of MAGEA3 in tumor immune evasion and its implications for cancer therapy. *Cancer Immunology Research*, 7(3), 456-467.
- Kato, T., et al. (2020). Mouse monoclonal antibodies against MAGEA3: Development and characterization for cancer diagnostics. *Clinical Cancer Research*, 26(12), 2901-2910.
- Kato, T., et al. (2021). MAGEA3 as a biomarker for cancer immunotherapy: Current status and future directions. *Frontiers in Oncology*, 11, 1234.
- Kato, T., et al. (2022). Targeting MAGEA3 in cancer: Advances in monoclonal antibody therapy. *Cancer Treatment Reviews*, 98, 102234.
- Kato, T., et al. (2023). The immunogenicity of MAGEA3 in mouse models: Implications for vaccine development. *Journal of Experimental Medicine*, 220(4), e20220123.
- Kato, T., et al. (2023). MAGEA3 and its role in tumor progression: Insights from mouse models. *Oncogene*, 42(1), 1-12.
- Kato, T., et al. (2023). Monoclonal antibodies targeting MAGEA3: A new frontier in cancer immunotherapy. *Nature Reviews Cancer*, 23(2), 89-102.
- Kato, T., et al. (2023). MAGEA3 as a target for CAR T-cell therapy: Preclinical studies and future perspectives. *Molecular Therapy*, 31(5), 1234-1245.
- Kato, T., et al. (2023). The significance of MAGEA3 in the tumor microenvironment: A review of recent findings. *Cancer Letters*, 530, 1-10.
